Welcome to our dedicated page for Pyxis Oncology news (Ticker: PYXS), a resource for investors and traders seeking the latest updates and insights on Pyxis Oncology stock.
Pyxis Oncology, Inc. develops clinical-stage cancer therapeutics, with news centered on micvotabart pelidotin, or MICVO, an investigational antibody-drug conjugate targeting extradomain-B fibronectin in the tumor extracellular matrix. Company updates focus on MICVO in solid tumors, including recurrent or metastatic head and neck squamous cell carcinoma, and on monotherapy and pembrolizumab combination development.
Recurring developments include clinical and preclinical data presentations, translational research on MICVO’s mechanism of action, quarterly and annual financial results, corporate presentations, leadership changes, business development appointments, and capital actions tied to funding the company’s oncology pipeline.
Pyxis Oncology (Nasdaq: PYXS) announced a conference call and live webcast on March 29, 2022, at 8:00 a.m. ET to discuss corporate updates. Interested parties can join via teleconference at (833) 945-2461 (domestic) or (520) 809-9726 (international) using Conference ID 5458057. The webcast can be accessed through this link or on their Investors section of the website. A replay will be available within two hours of the call and archived for 90 days. Pyxis Oncology focuses on difficult-to-treat cancers.
Axcella Therapeutics (Nasdaq: AXLA) announced the appointment of Robert Crane as its new Chief Financial Officer. Crane brings over 35 years of experience in life sciences, having raised over a billion dollars in capital and contributing significantly to previous companies' successes. Axcella's President, Bill Hinshaw, emphasized Crane's financial expertise and operational mindset at a pivotal moment for the company as it advances its clinical programs. Axcella aims to share crucial clinical data later this year, which may positively impact investor sentiment and facilitate growth opportunities.
Pyxis Oncology, Inc. (Nasdaq: PYXS) will be added to the Russell 2000® Index, effective December 20, 2021. This move follows the successful completion of their IPO in October 2021. The company, focused on developing next-generation therapeutics for challenging cancers, aims to leverage this inclusion to connect with a broader investor base. The Russell indexes are crucial for investment managers, with approximately $10.6 trillion in assets benchmarked against them.
Pyxis Oncology appoints Martina Molsbergen as Interim Chief Business Officer to enhance corporate strategy and business development efforts. With over 30 years of experience, Molsbergen will oversee existing partnerships and seek new opportunities. She has a proven record of over 450 successful deals and aims to leverage the company's $300 million raised in 2021 to advance its clinical trials. Under her leadership, Pyxis looks to grow through strategic collaborations and a robust development pipeline targeting challenging cancers.
Arrakis Therapeutics has announced the appointment of James Mutamba, PhD, as Chief Business Officer. Dr. Mutamba, who previously served as Vice President of Business and Corporate Development at Pyxis Oncology (NASDAQ: PYXS), brings extensive experience in business development and corporate strategy. He will lead Arrakis’s corporate strategy and business development efforts as the company advances its pipeline of RNA-targeted medicines. This strategic hire aims to capitalize on growth opportunities and strengthen investor relations.
Pyxis Oncology, Inc. (Nasdaq: PYXS) reported its third-quarter financial results for 2021, highlighting a strong cash position of approximately $283 million, expected to fund operations into late 2024. The company completed its IPO in October 2021, raising $168 million. R&D expenses surged to $7.8 million due to increased activities and personnel, while G&A expenses rose to $3.8 million. The net loss for the quarter was $14.2 million, or $8.96 per share, compared to a loss of $3.2 million in Q3 2020. The company aims to submit IND applications for its lead programs by 2022 and 2023.
Pyxis Oncology, Inc. (Nasdaq: PYXS) announced its participation in the virtual Jefferies London Healthcare Conference on November 18-19, 2021. The management will present and conduct one-on-one investor meetings. The presentation will be available on-demand starting November 18, and a replay will be accessible on Pyxis Oncology's website after the conference concludes. The company focuses on developing innovative cancer therapeutics, including antibody drug conjugates and monoclonal antibodies, to improve patient outcomes.
Pyxis Oncology, Inc. (Nasdaq: PYXS) has priced its upsized initial public offering at $16.00 per share, raising approximately $168.0 million before expenses. The offering consists of 10,500,000 shares, all offered by Pyxis, with trading on the Nasdaq expected to commence on October 8, 2021. The offering is scheduled to close on October 13, 2021. Additionally, underwriters have a 30-day option to purchase up to 1,575,000 additional shares. Pyxis, focused on developing next-generation cancer therapeutics, aims to improve patient quality of life.